National and Kapodistrian University of Athens
Μελέτη του οστικού μεταβολισμού στην εγκατάσταση των αρχέγονων αιμοποιητικών κυττάρων
Abstract
dc:descriptionAIMS: HSCT (hematopoietic stem cell transplantation) is a classic example of bone marrow microenvironment and HSC (hematopoietic stem cell) interaction. The role of bone tissue and endothelium in HSC trafficking has not been adequately studied in humans. The study of bone metabolism and angiogenesis during HSCT is the subject of the present work. PATIENTS AND METHODS: 29 patients (median age 38 years, males 66%, HL 48%, NHL 45%, MM 7%) were studied. Serum from each patient was collected before HDT (d-8 for lymphomas, d-4 for multiple myeloma), at the end of HDT (d-1), after the administration of HSC (d+1), at the nadir of myelotoxicity (d+5) and at the engraftment (d+10). The following markers were studied with ELISA: 1. Bone resorption markers (CTx, TRAP5b), 2. Bone formation markers (bALP, OCN), 3. Osteoblast inhibitors (Dkk1), 4. Osteoclastogenesis regulators (RANKL, OPG), 5. Angiogenic growth factors (Ang1, Ang2). RESULTS: 1. Bone resorption markers: CTx increases (not significantly) between the initiation (d-8/-4) and the end of HDT (d-1) and decreases until the engraftment (d-1 to d+10, p=0.005). Similarly, TRAP5b increases between d-8/-4 and d-1 (p=0.005) and decreases thereafter between d-1 and d+10 (p<0.001). 2. Bone formation markers: bALP decreases until the madir of myelotoxicity (d-8/-4 to d+5, p<0.001) and increases subsequently (d+5 to d+10, p=0.048). On the contrary, OCN decreases continuously during HSCT (d-8/-4 to d+10, p<0.001). 3. Osteoblast inhibitors: Dkk1 shows a similar pattern of variation to bALP as it decreases between d-8/-4 and d+5 (p<0.001) and increases thereafter (d+5 to d+10, p=0.008). 4. Osteoclastogenesis regulators: Due to the variations observed in RANKL and OPG the ratio RANKL/OPG shows no significant difference between d-8/-4 and d+5, but it increases between d+5 and d+10 (p=0.019). 5. Angiogenic growth factors: The changes of Ang1 and Ang2 lead to a progressive reduction of the ratio Ang1/Ang2 until the nadir of myelotoxicity (d-8/-4 to d+5, p<0.001) followed by a subsequent increase (not significant) until the engraftment. Furthermore, the levels of Ang1 and the value of Ang1/Ang2 ratio at d+1 correlate significantly with time to engraftment concerning neutrophil (cc=0.932, p<0.001 and cc=0.929, p<0.001 respectively) and platelet recovery (cc=0.727, p<0.001 and cc=0.709, p<0.001 respectively). The 140 number of CD34+ cells/kg of body weight infused was associated only with time to platelet engraftment (cc=-0.438, p=0.018) in this group of patients. When these variations were compared with the corresponding ones during conventional chemotherapy (CCT) intending to HSC mobilization it was shown that the last were similar to the first implying that these changes are due to similar events both in HSCT and CCT. CONCLUSIONS: Bone metabolism is clearly altered during autologous HSCT. The observed changes could be attributed to the toxic effect of HDT. However, it seems that the stress induced by HDT leads to bone remodeling that is characterised by osteoblast activation (increase in bALP after d+5) that intends to osteoclastogenesis and osteoclast activation (increase in RANKL/OPG ratio after d+5) and not to osteoid production (declining trend in OCN, reduction in Dkk1 after d+5). Probably, the initiation phase of bone remodeling that is not characterised by osteoclast activity and bone resorption (reduction in CTx and TRAP5b) takes place during HSCT. Considering the corresponding changes in bone metabolism markers during conventional chemotherapy intending to HSC mobilization it should be assumed that bone remodeling takes place in this case too as a result of the toxicity of chemotherapy. However, in this occasion it seems that the events represent a subsequent stage -initiation of bone resorption phase of bone remodeling?- (rising trend in TRAP5b even not significant). This may be attributed to the fact that osteoblasts have a major role in the procedure of engraftment, whereas osteoclasts have a leading role in the procedure of mobilization. Regarding endothelium it seems that the endothelial barrier disrupts under the effect of chemotherapy leading to the increase of the vascular permeability (prerequisite?) both in HSCT and in conventional chemotherapy (significant reduction of Ang1/Ang2 ratio). However, in the case of HSCT the rising trend of Ang1/Ang2 ratio (even not significant) after the nadir of myelotoxicity, probably, notifies the initiation of a procedure of vascular repair (enhancing effect in hematopoiesis?). Moreover, some markers, such as Ang1 and Ang1/Ang2 ratio at d+1 might predict engraftment even more strongly than the number of CD34+ cells infused.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Boutsikas, Georgios
- Μπούτσικας, Γεώργιος
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42581